Page 747«..1020..746747748749..760770..»

University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy – News 5 Cleveland

Posted: May 13, 2021 at 1:47 am

CLEVELAND When 61-year-old Ken Anderson was diagnosed with Multiple Myeloma 3 years ago, he didnt know what to expect.

It kind of hits you. It hits you hard, he said. Its a blood cancer, and its in your bone marrow, and it degenerates your bones is what it does.

The cancer is incurable, but treatable.

You live with it and you have to have many rounds of chemotherapy to keep the myeloma at bay, said Dr. Ted Teknos, the president of University Hospitals Seidman Cancer Center.

With so many unknowns, the dad of 4 girls and grandfather of 2 knew one thing, he was going to fight.

You just have to look to the road ahead, he said.

For the past 3 years, that road has been filled with ups and downs and countless rounds of chemotherapy treatments and even a bone marrow transplant.

They give you your stem cells back and those regenerate and lasted for about 6 months, and then there was a relapse, said Anderson.

Through it all, he remained hopeful for a medical breakthrough. He read about the research and followed up on the results of clinical trials in something called CAR T therapy.

I didn't know how far out that would be. It didn't say how far out it was. It sounded, to me, something like 10 or 20 years.

But it wasnt 20 years, the FDA approved CAR T therapy for Multiple Myeloma patients, and University Hospitals is the first in Ohio to treat patients with it. Anderson, who is from Kirtland, is the first patient in Ohio to receive it.

These treatments, now, are available for those that have run out of options, said Dr. Teknos.

Dr. Teknos compared the treatment to something straight out of a science fiction movie.

In essence, its like a heat-seeking missile for the cells to go find the cancer and eradicate it, he said.

It works by taking a patients own white blood cells, genetically modifying them in a lab and then infusing them back into their body so the patients cells can fight off the cancer cells.

They will engineer them to attack my cancer cells, said Anderson.

Dr. Teknos calls it living therapy.

You're taking living cells out of a patient, you're modifying them, and then you're growing them up in the lab and then re-infusing them back into the patient, he said. It's their own cells that have been modified and fight the cancer.

Dr. Teknos said in clinical trials, about 75% of Multiple Myeloma patients had a response to therapy, and in 1/3 of patients, their cancer went away.

Its really a game changer, said Dr. Teknos. There are patients who literally had weeks to live and then a year and a half later, have no cancer at all.

Andersons cells are currently in the lab. He will receive his infusion next month. He is cautiously optimistic that the next stop on his journey will have him feeling better.

I won't have to be on the chemo anymore, so I'm just back to feeling like myself would be would be really exciting, he said. People who are out there and diagnosed with this, with this disease, know that we are on the cusp of some big things here in the treatment of it, and this is a huge advance.

While Anderson is currently fighting Multiple Myeloma, University Hospitals is also offering a new CAR T cell therapy treatment for patients diagnosed with Diffuse Large B-Cell Lymphoma.

Read more here:
University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy - News 5 Cleveland

Posted in Ohio Stem Cells | Comments Off on University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy – News 5 Cleveland

AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; heres why – Market Globalist

Posted: May 13, 2021 at 1:47 am

In the premarket trading session, at last check AGE stock surged by 7.2% to $1.34. AGE stock closed previous session at $1.25 losing -3.85%. The AGE stock volume traded 80189.0 shares. In the past year up-to-date AGE stock had jumped by 64.47% while in the past week the shares shed -6.02%

On 1st April 2021, the AgeX Therapeutics Inc. announced the business update and release of financial results of the fourth quarter 2020.

5 Stocks Under $10 That Are Poised to Take Off

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Read More

The company had recently entered into a supported sponsored collaboration with The Ohio State Universit. This coordination is focused on the utilization of AgeX-BAT1 in mice. This candidate is based on AgeXs brown adipocyte tissue (BAT) cell treatment. The purpose of it is to decide if transplantation of AgeX-BAT1 cells may improve cardiovascular capacity, diet-incited obesity and metabolic wellbeing including glucose digestion.

AgeX has also partnered with a biopharmaceutical organization creating embryonic stem cell (ESC) derived mesenchymal stem cells (MSCs) known as ImStem Biotechnology Inc. The collaboration was based on non-exclusive sublicense that will contain royalties for the utilization of AgeXs clinical-grade ESC line ESI-053 to determine ImStems investigational MSC item candidate IMS001 for improvement in COVID-19 as well as acute respiratory distress disorder (ARDS) from different causes. ImStems MSC item up-and-comer IMS001 is based on AgeXs stem cell line ESI-053. In March 2020, IMS001 acquired FDA IND approval to start a human research in different sclerosis.

AgeX reported on March 12, 2021 the online distribution of research paper identifying with regeneration, maturing, and cancer in bioRxiv. The paper presents interesting information identifying with mechanisms that cells may use during the recovery period. The paper uncovers changes in specific qualities that may keep recovery from happening in aged people. It additionally gives proof that the group of qualities might be engaged with a wide exhibit of human tumors.

The fourth quarter and full year result for the year 2020 has overall positively improved as compared to the year 2019. When we look at the highlights posted by the company we see that the company for the fourth quarter of 2020 reported Total Revenues of $0.5 million. While for the year ended December 31, 2020 the total revenues were $1.9 million, compared to $1.7 million in the same period in 2019. The company increased the Operating expenses by $2 million to $12.4 million in full year 2020 as compared to 2019. The net loss attributable for AGE stock equals $0.29 per share in 2020 compared to $0.33 per share for the period 2019.

AgeX Therapeutics, Inc.,is a biotechnology company that specifically centers around the design, developmentand commercialization of novel therapeutics. These novel treatments areprimarily for human aging and degenerative illnesses. The organization was established in 2017 and is situated in Alameda,California.The company has its operations deployed in the market of United States. The organizations lead cell-based helpful candidate being developed consists of AGEX-BAT1, a cell treatment product for the treatment of different age-related metabolic issues, for example, Type II adult on-set diabetes.AgeX Therapeutics, Inc. has a research coordinated effort with the University of California, Irvine on neural foundational cell research program for Huntingtons sickness and other neurological disorders; and Sernova Corp.

The company also provides AGEX-VASC1, a cell-based treatment to reestablish vascular aid in ageing ischemic tissues, like the ischemic heart. Its lead drug-based investigative candidate is AGEX-iTR1547, for restoration of regenerative potential in a range of aged tissues affected by degenerative infections. Furthermore, the organization markets human embryonic stem cells; and GeneCards Database Suite, including genomic analysis calculations and analysis instruments for use by specialists at drug and biotechnology organizations, and different establishments.

Here is the original post:
AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; heres why - Market Globalist

Posted in Ohio Stem Cells | Comments Off on AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; heres why – Market Globalist

Gene therapy offers potential cure to children born without an immune system – UCLA Newsroom

Posted: May 13, 2021 at 1:46 am

An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited disorder that leaves them without an immune system.

Severe combined immunodeficiency due to adenosine deaminase deficiency, or ADA-SCID, is caused by mutations in the ADA gene that creates the enzyme adenosine deaminase, which is essential to a functioning immune system. For children with the condition, even day-to-day activities like going to school or playing with friends can lead to dangerous, life-threatening infections. If untreated, ADA-SCID can be fatal within the first two years of life.

The investigational gene therapy method involves first collecting some of the childs blood-forming stem cells, which have the potential to create all types of blood and immune cells. Next, using an approach developed by the research team, a new copy of the ADA gene is delivered into the stem cells by a modified lentivirus, or viral vector. The corrected cells are then returned to the childs body, where they are intended to produce a continual supply of healthy immune cells capable of fighting infection.

In a studypublished today in the New England Journal of Medicine, co-lead authors Dr. Donald Kohn of UCLA and Dr. Claire Booth of Great Ormond Street Hospital, or GOSH, report two- and three-year outcomes for children treated with the investigational lentiviral gene therapy in clinical trials at GOSH, UCLA Mattel Childrens Hospital and the National Institutes of Health between 2012 and 2017.

Between all three clinical trials, 50 patients were treated, and the overall results were very encouraging, said Kohn, a distinguished professor of microbiology, immunology and molecular genetics and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. All the patients are alive and well, and in more than 95% of them, the therapy appears to have corrected their underlying immune system problems.

No complications or treatment-limiting events were reported among the patients. Most adverse events were mild or moderate, and were considered to be related to routine procedures performed in preparation for the experimental gene therapy treatment or effects of the immune system rebuilding.

Treatment was successful in all but two of the 50 cases, and both of those children were able to return to current standard-of care-therapies and treatments, with one eventually receiving a bone marrow transplant, said Kohn, who has been working to develop gene therapies for ADA-SCID and other blood diseases for 35 years.

The investigational gene therapy a one-time procedure that the researchers say may provide lifelong results is a welcome potential new treatment option for children with ADA-SCID, who otherwise must undergo once- or twice-weekly injections of the ADA enzyme until a matched bone marrow donor, usually a close family member, can be found. If a donor is not available, patients require lifelong injections, along with antibiotics, antifungal medications and monthly infusions of immunoglobulin, which contains infection-fighting antibodies. These treatments are expensive and therefore out of reach for patients in many countries.

If approved in the future, this treatment could be standard for ADA-SCID, and potentially many other genetic conditions, removing the need to find a matched donor for a bone marrow transplant and the toxic side effects often associated with that treatment, said Booth, a GOSH consultant inpediatric immunology and genetherapy.

The benefits of lentiviral gene therapy

Prior to teaming up, both Booth and Kohn worked separately for years onsuccessful gene therapiesfor ADA-SCID that used viral vectors made from retroviruses. Retroviral vectors, however, can only enter cells nuclei to deliver genes while the cells are dividing, limiting the number of cells receiving the genetic payload and, thereby, the potential efficacy of the treatment.

Additionally, while neither Kohn nor Booth observed serious complications in their ADA-SCID trials, other earlier studies testing retroviral vector-based gene therapies did report some serious side effects, including leukemia, in some patients.

In 2008, Booth and Kohn began collaborating with professors Bobby Gaspar and Adrian Thrasher of University College London to develop an improved viral vector using a different kind of virus, called a lentivirus. Viruses of this kind can enter non-dividing cells nuclei and, when used as vectors, have the potential to make gene therapies safer and more effective. ADA-SCID patients began receiving the new gene therapy at GOSH in 2012; the following year, the experimental treatment was offered at UCLA and the NIH.

More than 200 patients with various genetic conditions across the worldhave now been treatedwith experimental lentiviral gene therapies, and applying gene therapy to ADA-SCIDis another significantscientific advance, said Thrasher, a senior author of the study who is also a professor of pediatric immunology at GOSH.

Ten of the children in the UCLA study were treated using a frozen preparation of corrected stem cells. These children experienced similar outcomes to the children treated with cells that were not frozen. The freezing approach may allow children with ADA-SCID to have their stem cells collected locally, then have them transported and processed at a manufacturing facility elsewhere and shipped back to a specialized hospital near them, removing the need for patients and their families to travel long distances to specialist centers.

One patients story: A life-changing treatment

Courtesy of Chelsea Oakley

One of the patients who received a frozen preparation of cells at UCLA, Cora Oakley of Morristown, New Jersey, was diagnosed with ADA-SCID through newborn genetic screening at just 7 days old, in April 2017.I remember asking the doctor if my daughter was going to die, Coras mother, Chelsea Oakley, said of receiving the diagnosis. And his response was, I hope not. It was the darkest day of my life.

Cora was the last child to enroll in the clinical trial and received her own corrected cells in September 2017.Following the gene therapy, Cora and her family spent a month in the bone marrow transplant unit of a hospital closer to their home for Coras follow-up treatment. The experiences of the other young patients in this unit opened Oakleys eyes to what her daughter would have gone through if the experimental gene therapy hadnt been an option.

I saw young bone marrow transplant patients who developed graft-versus-host disease and others who had to take all these anti-rejection medications and still had issues. I just thought no one should have to suffer like this, she said. And then heres my daughter who had this life-changing treatment that felt like a miracle. It still shocks me all the time how unbelievably fortunate we are.

Now a healthy and exuberant 4-year-old, Cora is described by her mom as a rough and tumble, outdoors kind of kid who loves all animals and is incredibly social. Ill never forget what it felt like when we didnt know if shed ever be able to do any of these things, Oakley said.

The investigational lentiviral gene therapy is licensed to Orchard Therapeutics and has not been approved for clinical use by any regulatory authority.

The research was funded by the National Institute of Allergy and Infectious Diseases, the National Heart, Lung and Blood Institute, and the National Human Genome Research Institute (all part of the U.S. National Institutes of Health); the California Institute for Regenerative Medicine; the U.K. National Institute for Health Researchs Biomedical Research Centre at Great Ormond Street Hospital for Children National Health Service Foundation Trust, University College London and Orchard Therapeutics.

Continued here:
Gene therapy offers potential cure to children born without an immune system - UCLA Newsroom

Posted in New Jersey Stem Cells | Comments Off on Gene therapy offers potential cure to children born without an immune system – UCLA Newsroom

Commencement stories from Rowan paint a picture of opportunities near and far – NJ.com

Posted: May 13, 2021 at 1:46 am

When Ashley Hopkins walks across the stage Wednesday during a commencement ceremony at Rowan University, she will be sharing it with her brother thousands of miles away.

Brett Hopkins is deployed overseas with the New Jersey National Guard Air Force but Ashley will symbolically accept his diploma for a bachelors degree in finance, magna cum laude. She has also earned a degree from the William G. Rohrer College of Business.

I wasnt going to walk because I have one more semester for my double major in human resources, Ashley said during an interview with NJ Advance Media. But I still have enough credits for the degree now. Were both first-generation for a degree in our family and I know its something that makes my mother really proud.

The Hopkins are among a group of standout graduates singled out by Rowan during this commencement. Others include Katherine Trauger, who is headed to the University of Oxford, London, on a full scholarship for a Masters Degree and Gatha Adhikari, who survived a deadly earthquake in Nepal in 2015 and now has a bachelors degree in biomedical engineering. She is on her way to the University of Maryland for a masters and doctoral program.

Brett Hopkins, 23, sent a video and a photo of him accepting his diploma cover at an undisclosed location overseas. It is scheduled to be featured during some of the 20 socially-distanced commencement ceremonies over four days on Saturday, Monday, Wednesday and Thursday.

He is a year older than Ashley but began college a year later. Both commuted from the Sicklerville section of Gloucester Township to Rowans main campus in Glassboro some 9 miles away.

About half of Rowans 19,000 students are commuters. The remainder live on or near the 800-acre Glassboro campus.

I did my first two years at Camden County College, Ashley said. I didnt need the full college experience. I dont think there is anything wrong with that. Everyone can have a different education and still have a good outcome.

Ashley Hopkins, right, accepted her and her brother's diploma covers during a commencement ceremony Wednesday at Rowan University, N.J. Brett Hopkins, her brother, abroad for a N.J. Air National Guard deployment.

Ashley aspires to work in human resources and is completing an internship now with an office products company. She is not sure what her brother plans to do after his deployment but said he was recently promoted to lieutenant.

Katherine Trauger, 22, of Cherry Hill, said Rowan was her safe school when she was applying to colleges. She initially wanted to pursue a career in music. Her mother is a professional opera singer and she thinks spending hours at her rehearsals when she was a child helped shape her world view.

But she decided to attend Rowan and pursue history and political science instead. Her commencement ceremony will be held Thursday.

My mother has always told me to go for it, reach for the stars, she said. Ive always been adventurous.

But she also proved to be practical. She said she couldnt turn down the scholarship package from Rowan. She also quickly learned her instructors inspired her to do great things, like dream of going abroad to attend one of the most prestigious universities in the world.

I have a professor from the history department who went to Oxford to get his degree, Trauger said. He had kind of been my mentor and was always saying you can do this Katherine you can go to the London school of economics. All along I was saying its just not possible. Its just not going to happen.

But it did.

Trauger said she plotted a path forward. It included getting published, volunteering for campaign work with local politicians and getting hired to work at a policy think tank in Philadelphia.

Kathrine Trauger graduated with a bachelor's degree in history and political science from Rowan University on Thursday.

On a whim, I sent my resume into the Foreign Policy Research Institute in Philadelphia and this man Clint Watts, a political commentator and researcher on MSNBC, emailed me. He saw my resume and thought I would be a great fit.

Watt, also a former FBI agent, is working on a study on foreign intervention in the U.S. election.

I joined this research team with kids from Harvard, Yale, Stanford, Brown and then theres me from Rowan, she said. The key thing was getting myself off campus and finding these experiences. Its a good reminder that people who are going to change the world are coming from these small state schools.

Trauger is preparing to cross an ocean in the fall to continue her academic journey. Gatha Adhikari crossed the same ocean four years ago to begin hers at Rowan.

It has been great, but its kind of bittersweet, Adhikari said during a telephone interview this week as she prepared for her commencement ceremony Monday.

My family could not be here because of COVID, Adhikari said. They are back home in Nepal. Four years ago when I came here I was alone. Today I have friends and support from everyone. I came a long way but it was worth it.

Adhikari said her entire village of Begnastal were planning to watch a live stream of her 1 p.m. ceremony. Nepal is 9 hours and 45 minutes ahead of time in New Jersey. Her village has a total population of about 300, she said. Nepal is a landlocked country in the Himalayas sandwiched between India and the Tibet region of China. Mount Everest is there and the exotic local of Kathmandu.

Back when I was a girl I never dreamed about being here, she said. Biomedical engineering for a little girl seemed impossible. It shows its possible if you believe in yourself.

Adhikari survived a 7.8 richter scale earthquake in Nepal in 2015 that killed nearly 9,000 people and destroyed more than 600,000 structures. She said she was away at school when just about everything came crashing down. Many of the buildings were made of mud and stone and laid in ruins around her. She said they lived outdoors in tents for more than a week and experienced anxious hours afterward until she was able to reach her parents.

That experience helped to shape her future aspirations.

Gatha Adhikari accept her bachelors degree in biomedical engineering this week at Rowan University, N.J.

Thats one of the reasons I decided to go into biomedical research, she said. I felt so helpless after the quake. I thought if I pursued this I would be able to help people.

Adhikaris research at Rowan involves making gels with regenerative stem cells. The research could help regrow skin that has been damaged.

She said she won a Fulbright scholarship when she was in high school in Nepal. That helped her go abroad for school. She chose Rowan because of its engineering program and its affordability.

Now she is a mentor for three male students from Nepal who also attend Rowan.

Im like their mother, she said. I do everything for them. I was like an alien when I first came. I can vibe with the people now. This is my home.

Please subscribe now and support the local journalism YOU rely on and trust.

Bill Duhart may be reached at bduhart@njadvancemedia.com.

Read this article:
Commencement stories from Rowan paint a picture of opportunities near and far - NJ.com

Posted in New Jersey Stem Cells | Comments Off on Commencement stories from Rowan paint a picture of opportunities near and far – NJ.com

Not Even This by Jack Underwood review fatherhood, philosophy and fear – The Guardian

Posted: May 13, 2021 at 1:45 am

About three years ago, the poet Jack Underwood became a father for the first time. The responsibility weighed heavily: he recalls feeling that there should have been more paperwork. We signed a form or two and then they just sort of let us take you away. A human child. A few months later, he started having panic attacks his love for his daughter had rendered him utterly fucked with worry. He decided to write about it, which helped: my breathing regulated, my thoughts took shape, giving direction to my feelings; finding my thinking voice was like opening an enormous valve. The resulting book is a thoughtful essay-memoir on parenthood, in which Underwood recounts how he learned to manage his angst to live within the fear by embracing uncertainty.

Not Even This takes its title from the ancient philosopher Carneades of Cyrene, who remarked that Nothing can be known; not even this. It is a hybrid work, alternating between two distinct modes of writing: an epistolary memoir in the second person, addressed to the authors daughter; and a freewheeling meditation on the theme of uncertainty, touching on assorted matters of quantum physics, neuroscience, etymology, history, economics and technology. These include, among other things, the disagreement between Albert Einstein and Henri Bergson as to whether time exists independently of human beings; the biomedical ethics of transhumanism; the prospect of the technological singularity, when digital superintelligence will transcend the human intellect; the way time seems to slow down when were doing something interesting; the anomalousness of wave-particles; the reality behind the myth of Joan of Arc.

The gist? Knowledge is inherently tenuous, mutable renegotiable, political and socialised, and the craving for certainty is at the root of many societal ills. The financial system, for example, is wedded to certain rigid orthodoxies that are periodically disproved, with disastrous consequences: When we mistake the power of finance for certainty in its workings, then we only hand it more power, more confidence, and so permit it to act less and less reasonably. Fallibility is integral to human progress, so its best to go with the flow: a parent has little choice but to learn to trust a child to become themselves, and such trust is a kind of love.

The idea of trust also informs his approach to creative writing. Underwood, whose first poetry collection, Happiness, was published by Faber in 2015, sees poetry as a form of dissonant, unruly, uncertain knowledge, in which language is provisional, equivocal, interpretable. The process of composition is built on two-way trust: trusting the reader to get it, and trusting yourself, as a writer, to make yourself understood. Unlike many poets, Underwood doesnt save multiple drafts of his poems, but restricts himself to a single document and if I ruin it well, never mind Maybe I need the fear, the slight risk, to force myself to take responsibility for the poem in my care I have to move forwards in one vulnerable, resolute trajectory.

Underwood rejects the platitudinous notion that having kids turns you into a better person If anything parenthood has made us more selfish, more insular, always directing our hearts resources inwards. But he is, by his own account, a sentimental sort (I find old batteries funereal. I thank cash machines and postboxes), and this is what gives this book its charm. He reminisces fondly about his daughters first unaided steps, and sympathetically recalls how, during the first few months of her life, she would become extremely unsettled a neurotic, crotchety recluse whenever he had guests round: A roomful of strangers bursting out laughing must have been a grotesque, hyperreal tableau of teeth and gums. He believes silliness is intrinsic to intimacy, and encourages her to feast, you daft little cherub. There is practically nothing in life better than being incredibly silly. Elsewhere, overcome with love, he gushes endearments: My bag of fish. My cuddling gammon. Look at you go! Jesus Christ. Let me count the ways.

This is Underwoods first book of nonfiction prose and, like most debuts, it has its flaws. The central argument is somewhat woolly almost any subject might be obliquely tethered to uncertainty and Underwoods rhapsodic lyricism sails dangerously close to feyness at times. But he is a lucid and engaging companion. The voice that comes through in these pages is immensely likable humble, conscientious and emotionally intelligent. The books format flitting back and forth between disquisition and memoir every few pages serves the reader well: the essayistic meanderings are kept in check, and the autobiographical candour doesnt cloy.

A number of recent books on fatherhood have examined the subject through the prism of masculinity. These include Charlie Gilmours Featherhood (2020), Caleb Klaces Fatherhood (2019), Toby Litts Wrestliana (2018), Howard Cunnells Fathers and Sons (2017) and William Giraldis The Heros Body (2017). Though Not Even This also touches questions of gender, the scope of its existential inquiry is broader: Underwoods overarching theme is fear and fear, as he rightly points out, is what underpins the less savoury aspects of conventional masculinity. For all his fretfulness, this is an upbeat book. Underwoods dread gave way to a sanguine sense of purpose and self-sacrifice: Ive experienced a shift in my personhood, he writes, and acquired this sense of my body as happy collateral, a buffer of meat. Im not the important one in my life any more.

Not Even This: Poetry, Parenthood & Living Uncertainly by Jack Underwood is published by Corsair (14.99). To order a copy go to guardianbookshop.com. Delivery charges may apply.

More:
Not Even This by Jack Underwood review fatherhood, philosophy and fear - The Guardian

Posted in Transhumanism | Comments Off on Not Even This by Jack Underwood review fatherhood, philosophy and fear – The Guardian

Global Testosterone Replacement Therapy Market Analysis, Size, Share, Growth, Trends, and Forecast 2021-2025 Clark County Blog – Clark County Blog

Posted: April 29, 2021 at 1:53 am

Covid-19 Update Report: A report titled Global Testosterone Replacement Therapy Market 2020 Analysis, Size, Share, Growth, Trends, and Forecasts, using a variety of methodologies from 2021-2025 to analyze and present detailed and accurate data on the global Testosterone Replacement Therapy market. The report is divided into various well-defined sections to provide the reader with a simple and easy-to-understand information document. In addition, each section details all the data needed to gain knowledge about the market before entering the market or strengthening your current foothold.

Find out how COVID-19 has affected the growth of the industry. Get a free sample report with detailed analysis @

https://www.globalmarketers.biz/report/life-sciences/global-testosterone-replacement-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/129647#request-sample

Methodology

The Leading Manufacturers Analysis:

AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

Regional Analysis

Do Inquiry Before Buying https://www.globalmarketers.biz/report/life-sciences/global-testosterone-replacement-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/129647#inquiry_before_buying

Market Segments Analysis:

Application Analysis:

HospitalsClinicsOthers

Type Analysis:

GelsInjectionsPatchesOther

Download a free sample report with all tables and graphs

https://www.globalmarketers.biz/report/life-sciences/global-testosterone-replacement-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/129647#request-sample

This report segmented into 13 segments are as follows:

Segments 1 and 2: Market definitions, Testosterone Replacement Therapy market scope, classifications, applications, market concentration, and market size calculations are analyzed in this segment. In addition, the market presence across different regions and market statistics for these regions will be assessed from 2015 to 2019. Testosterone Replacement Therapy Production and growth rates are analyzed in each region. It also provides comprehensive coverage of industry policies and plans, market drivers, constraints, and the latest industry news.

Segments 3 and 4: Testosterone Replacement Therapy Industrial Chain Structure, Production Volume, Raw Material Costs, Manufacturing Costs, Market Leading Testosterone Replacement Therapy Players, Supplier, and Buyers are investigated. Testosterone Replacement Therapy Market classifications by type include growth rate, price analysis, value and quantity analysis, and market share.

Segments 5 and 6: This segment evaluates consumption and market share based on Testosterone Replacement Therapy applications. This segment also surveys region-based Testosterone Replacement Therapy production and gross margins.

Segments 7 and 8: Under this segment, top players competitive landscape views, company profile, market position, production volume, and regional analysis will be studied.

Segments 9 and 10: This segment provides forecast Testosterone Replacement Therapy information based on market value and volume. It also provides regional forecasts for North America, Europe, China, Japan, the Middle East, India, and South America from 2020 to 2025

Segments 11, 12, and 13: This segment provides feasibility analysis, industry barriers, investment opportunities, and valuable conclusions. In addition, detailed survey methods and data sources are provided in this survey report.

Therefore, comprehensive studies based on Testosterone Replacement Therapy, key segments, growth trends, revenue and volume forecasts, and market size estimates are shown in this report.

Browse Full TOC, [emailprotected] https://www.globalmarketers.biz/report/life-sciences/global-testosterone-replacement-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/129647#table-of-contents

See the original post here:
Global Testosterone Replacement Therapy Market Analysis, Size, Share, Growth, Trends, and Forecast 2021-2025 Clark County Blog - Clark County Blog

Posted in Testosterone Replacement Therapy | Comments Off on Global Testosterone Replacement Therapy Market Analysis, Size, Share, Growth, Trends, and Forecast 2021-2025 Clark County Blog – Clark County Blog

Olive Oil Consumption Increases Testosterone in Men With Insufficient Levels – Olive Oil Times

Posted: April 29, 2021 at 1:53 am

Newly-published research shows that following alow-fat diet may lower testosterone levels in men by up to 15 percent.

While the study suggests that low-fat diets may negatively impact the production of the important hormone, one of its co-authors said supplementing with extra virgin olive oil may help.

Our results show that going from adiet of 40 percent fat to adiet of 20 percent fat decreases testosterone levels by about 11.5 percent on average, and 15 percent in men of European descent, said Joe Whittaker, co-author of the study and anutritionist and researcher at the University of Worcester.

To put this into context, most men in Western countries eat around 35 percent [fat in their diet], he told Olive Oil Times. So, if these men try alow-fat diet, their testosterone will probably decrease.

The researchers selected six previous studies to gather and analyze testosterone variations on asample of 206 participants. These studies found that testosterone production may be boosted by high intakes of monounsaturated fats such as those found in olive oil, avocados and nuts.

According to the studys authors, there is scientific evidence about asuperior efficacy of higher fat diets than low-fat diets.

This is particularly true with diets high in healthy fats such as monounsaturated and polyunsaturated fats, Whittaker said. The Mediterranean diet is aperfect example of this.

Our study indicates that diets high in monounsaturated fats may boost testosterone production, he added. This is supported by other research. For instance, one study found that replacing butter with olive oil increased mens testosterone by 17.4 percent.

Whittaker emphasized that olive oil consumption is asafer way for men to optimize testosterone levels, which are critical for male sexual and mental health, while not increasing their risk of heart disease.

Many studies link low testosterone to depression, cardiovascular disease, diabetes, Alzheimers disease and other diseases, Whittaker said. Although these studies are only associations, there are some strong causal links between low testosterone and an increased risk of disease.

He also emphasized how previous meta-analyses found that giving testosterone replacement therapy to men with low testosterone and diabetes improved their wellbeing.

The researchers have also speculated that the lower testosterone levels induced by low-fat diets might occur more often in men of European descent. Whittaker said he thinks this may be due to the evolutionary history of men with European ancestry.

Plants do not grow well in the winter, particularly in Northern Europe, so our ancestors were forced to survive on high-fat animal foods, he said.

After the agricultural revolution, which took place about 10,000years ago, Whittaker said that Europeans continued to eat high-fat diets, with dairy and cheese becoming astaple.

Also, olives have been astaple crop in the Mediterranean for thousands of years, so there is probably some adaptation to ahigh-fat diet in those areas too, he said. In contrast, if you think of somewhere like Japan, their traditional diet is heavy in rice and seafood and is essentially alow-fat diet.

Whittaker theorizes that populations that evolved eating alow-fat diet were less likely to have their testosterone levels negatively impacted but emphasized that further research is needed to confirm this.

Whittaker said that the researchers are currently investigating the steady decrease of testosterone levels in men from industrialized countries, which has been happening since the 1970s.

The research so far has largely focused on charting the decline in testosterone, Whittaker said. There has also been alot of research into the decline in sperm counts. Alarge study found sperm counts have decreased by 59.3 percent in Western countries from 1973 to 2011.

So, we can see male reproductive health across the board (testosterone and sperm levels) is declining quite rapidly, he added.

While chemicals in plastics and other consumer goods probably play arole in what is happening, another factor is diet, said the researcher.

Diet quality has decreased, and processed food intake has increased, Whittaker said. Obesity and diabetes have risen dramatically since the 1970s, obesity has nearly tripled worldwide since 1975, and both of these have strong adverse effects on testosterone levels.

Read more here:
Olive Oil Consumption Increases Testosterone in Men With Insufficient Levels - Olive Oil Times

Posted in Testosterone Replacement Therapy | Comments Off on Olive Oil Consumption Increases Testosterone in Men With Insufficient Levels – Olive Oil Times

New Research: Testosterone Replacement Therapy Market 2026 Industry Specifications and Outlook 2021| Endo International, AbbVie, Eli lilly, Pfizer,…

Posted: April 29, 2021 at 1:52 am

Global Testosterone Replacement Therapy Industry: with growing significant CAGR during 2021-2026

Trending Testosterone Replacement Therapy Market 2021: COVID-19 Outbreak Impact Analysis

Chicago, United States ,The report entitled Global Testosterone Replacement Therapy Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 released byReport Hive Researchcomprises an assessment of the market which provides the real-time market scenario and its projections during 2021 to 2026 time-period. The report offers an understanding of the demographic changes that took place in recent years. The report presents an analysis of market size, share, growth, trends, statistical and comprehensive facts of the global Testosterone Replacement Therapy market. This research study presents informative information and in-depth evaluation of the market and its segments based totally on technology, geography, region, and applications.

The report highlights several significant features of the global Testosterone Replacement Therapy market encompassing competitive landscape, segmentation analysis, and industry environment. It shows the scope of the market and a brief overview of the definition and description of the product or service. The potential factors that can bring the market to the upward direction have been mentioned in the report. With this report, companies, as well as individuals interested in this report, will get proven valuable guidelines and direction so that they consolidate their position in the market.

The major players and the new entrants have been incorporating strategic merger and acquisition activities amongst each other to testify the factors responsible for changing dynamics. These changing dynamics implore the players to keep up with rising demands or present restrains so as to drive the broad scope of the global Testosterone Replacement Therapy Market.

>>>>The study encompasses profiles of major companies operating in the global Testosterone Replacement Therapy Market. Key players profiled in the report include: Endo International, AbbVie, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Analysis of Global Testosterone Replacement Therapy Market By Type: GelsInjectionsPatchesOthers

Analysis of Global Testosterone Replacement Therapy Market By Application: HospitalsClinicsOthers

Drivers And Risks:The report covers the basic dynamics of the global Testosterone Replacement Therapy market. It scrutinizes several data and figures, and numerous volume trends. A number of potential growth factors, risks, restraints, challenges, market developments, opportunities, strengths, and weaknesses have been highlighted. Another factor affecting market growth has also been included in the report.

Regional Analysis:The report comprises of regional development status, covering all the major regions of the world. This regional status shows the size (in terms of value and volume), and price data for the global Testosterone Replacement Therapy market. The development of the industry is assessed with information on the current status of the industry in various regions. Data type assessed concerning various regions includes capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export, etc.

Report offers:

>>>>Get Full Customize report @ https://www.reporthive.com/request_customization/2507819

Regional coverage:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2021 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Testosterone Replacement Therapy market.

Chapter 2: Evaluating the leading manufacturers of the global Testosterone Replacement Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3: the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4: Presenting global Testosterone Replacement Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Profiling Key players: Endo International, AbbVie, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

In this report, Leading players of the global Testosterone Replacement Therapy Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Testosterone Replacement Therapy Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Testosterone Replacement Therapy Market. It also provides useful recommendations for new as well as established players of the global Testosterone Replacement Therapy Market.

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2507819

Testosterone Replacement Therapy Market CAGR Competitive Landscape, Market Research, Testosterone Replacement Therapy Market Best Companies in The world , Testosterone Replacement Therapy Market Top Companies in The world, Testosterone Replacement Therapy Market Trend, Testosterone Replacement Therapy Trends, Testosterone Replacement Therapy growth, Testosterone Replacement Therapy industry, Testosterone Replacement Therapy Covid-19 Impact Analysis

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :Report Hive Research500, North Michigan Avenue,Suite 6014,Chicago, IL 60611,United StatesPhone:+1 312-604-7084

Read more from the original source:
New Research: Testosterone Replacement Therapy Market 2026 Industry Specifications and Outlook 2021| Endo International, AbbVie, Eli lilly, Pfizer,...

Posted in Testosterone Replacement Therapy | Comments Off on New Research: Testosterone Replacement Therapy Market 2026 Industry Specifications and Outlook 2021| Endo International, AbbVie, Eli lilly, Pfizer,…

Testosterone Replacement Therapy Market: Growing Awareness about Testosterone Replacement Therapy to Drive Market – BioSpace

Posted: April 29, 2021 at 1:52 am

Transparency Market Research (TMR) has published a new report titled, Testosterone Replacement Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the global Testosterone Replacement Therapy market was valued at US$ 1,613.7 Mn in 2018 and is projected to expand at a CAGR of 4.4% from 2019 to 2027.

Overview

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

Growing Awareness about Testosterone Replacement Therapy to Drive Market

Request for Analysis of COVID19 Impact on Testosterone Replacement Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1097

North America to Dominate Global Market

Buy Testosterone Replacement Therapy Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1097&ltype=S

Competitive Landscape

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read more from the original source:
Testosterone Replacement Therapy Market: Growing Awareness about Testosterone Replacement Therapy to Drive Market - BioSpace

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market: Growing Awareness about Testosterone Replacement Therapy to Drive Market – BioSpace

Breakthrough gene therapies in sight | UNC-Chapel Hill – UNC Chapell Hill

Posted: April 29, 2021 at 1:51 am

Patients withgeneticlysosomal storagediseases particularly children are living longer because of better treatments. But with promising advances and longer lives comes complications, the loss of eyesight as these rare diseases take their toll over time.

Lysosomal storage diseases are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the bodys cells as a result of enzyme deficiencies, according to theNational Organization for Rare Disorders. With these diseases, patients are missing the mucopolysaccharidosis type 1 (MPS1) gene. Current therapies that allow patients to live longer dont address corneal clouding caused by these diseases. However, one Carolina-affiliated startup, RainBio, isdeveloping anovel gene therapyforMPSI corneal blindness, giving patients a chance not only for longer lives but better ones.

The companys treatment, RBIO-1, is poised to meet a large unmet medical need in ophthalmology.Co-foundedbyMatt Hirsch,associate professor of ophthalmology at the UNC Gene Therapy Center, RainBio is the only ocular gene therapy pioneer focused on blindness in the cornea. The companys adeno-associated virus vector gene therapy can directly correct cornea cellular function to maintain or restore vision in patients at risk of blindness. The companys first candidate is a groundbreaking, first-in-class lead program for corneal clouding in MPS1 patients who have vision loss.

As we look at what is being done in the ophthalmology space, we see that most [adeno-associated virus] therapeutics are focused on the back of the eye the retina, but nobody seems to be looking at the front of the eye the cornea, says Fran Martin, RainBio president. If we can provide those affected with lysosomal storage diseases a mechanism where they can see, theyd be able to have a better quality of life.

The idea for RainBios treatment started less than five years ago, when Dr. Joanne Kurtzberg, a pediatric bone marrow transplant specialist, who conducts stem cell transplants in children with lysosomal storage diseases at Duke, met with Hirsch and Samulski to figure out how to potentially address the blindness that comes with lysosomal storage disease. Kurtzberg works with stem cell therapies that can extend the longevity of life for kids affected but dont address the loss of sight. Hirsch realized if he could replace the missing gene in the cornea, those kids could regain their sight.

With our product, you inject the missing gene right into the cornea, says Martin. This allows for prevention of corneal clouding or blindness, and can even reverse the blindness or cornea clouding if the treatment is given early enough.

For kids who are losing their sight, another option is to have a cornea transplant. But those transplants dont come without risk.

Corneal transplants can sometimes result in high rejection rates and potential infection, adds Martin. We can offer an additional treatment that patients can try before moving to a transplant.

The RainBio team often collaborates with colleagues at local universities as well asJoseph Muenzer,a professor of pediatric genetics and metabolism at the School of Medicine, who treats children affected bylysosomal storage diseases.Jude Samulski, professor of pharmacology at the Gene Therapy Center in the UNC School of Medicine and a pioneer in gene therapy, also contributed to the patents for the product.

A lot of expertise in gene therapy was developed over the past few decades at UNC, says Martin. That expertise has benefited RainBio, and weve benefited from the input into the science around our product as well.

To make the best use of resources, the RainBio team benefits from collaborating withKickStart Venture Services as well as Carolinas Office of Technology Commercialization. KickStart supports faculty startup formation, business development and growth by providing coaching and mentoring, early-stage funding, connection with key service providers, management, investors and space. Both KickStart and the Office of Technology Commercialization. are part of Innovate Carolina, the University-wide initiative for innovation and entrepreneurship.

Its been a pleasure to work with KickStart and OTC to really get the guidance and resources needed as weve grown as a company, says Martin. They helped us work through the Carolina Express License and have been very supportive in helping us to understand the process as well as in providing resources as we think through our strategy as a growing company.

The Carolina Express license assists Carolina startups by streamlining and speeding the path for UNC-Chapel Hill faculty, students or staff startup founders to translate new discoveries into useful products.

Alongside Epigenos Bioscience, the RainBio team also had the opportunity in fall 2020 to present to approximately 20 advisors who gave them advice on how to continue commercializing their technology and growing their business, even in the midst of a pandemic. This is one of the programs that Kickstart adapted online to continue providing support for startups. Advice and guidance offered at advisory meetings includes anything from R&D to fundraising and strategy. Other startup companies that would like to present can get in touch with KickStart to be considered for a future meeting.

In addition, RainBio received a $100,000 loan fromNCBiotechas well as support from theMPS Society, which funded a key rabbit toxicology study. RainBio also collaborated with NC State University through co-founderBrian Gilger, who has conducted the toxicology studies at the NC State School of Veterinary Medicine.

And for patients who are ready to try RainBiosRBIO-1 treatment,Martin says the idea of a one-time dose is promising.

Although we are still testing the product, whats also unique about this treatment is that only one dose may be required. In addition, a very small amount of product around 250 times less will be needed compared to other treatments on the market for retinal blindness, she adds.

Although the company only launched in June 2020, RainBio already has pre-clinical efficacy and safety data and is poised to meet with the US Food and Drug Administration.

Even though were not even a year old, we have orphan drug designation and rare pediatric disease designation that was granted to us by the FDA, says Martin. We have pre-clinical efficacy in theMPS1canine model, and 100 percent prevention and reversal of cornea blindness.

RainBio is developing aplatform for additional treatmentsfor blinding corneal diseases.

There are several Lysosomal storage diseases that have the same cornea blindness issue, says Martin. Although its a different gene that is missing, we believe as we prove this concept inMPS1patients, then it will be translatable to otherlysosomal storagediseases.

As RainBio continues to grow and develop its product, next steps include accessing additional funding to manufacture the product and get it into the clinic.

See the rest here:
Breakthrough gene therapies in sight | UNC-Chapel Hill - UNC Chapell Hill

Posted in Gene therapy | Comments Off on Breakthrough gene therapies in sight | UNC-Chapel Hill – UNC Chapell Hill

Page 747«..1020..746747748749..760770..»